Vandetanib failed to reduce time to progression (TTP) among patients with small cell lung cancer (SCLC), according to an article published in Cancer.1

Researchers enrolled 74 patients to this phase 2 trial, none of whom were treated previously. Sixty-six were randomized to 1 of 2 arms: platinum therapy, etoposide, and placebo, or platinum therapy, etoposide, and vandetanib.

Of all enrolled patients, 31 were evaluated from either cohort. Median TTP was 5.62 months with vandetanib; median TTP with placebo was 5.68 months. Overall survival, however, was more than 4 months longer with vandetanib (13.24 months versus 9.23 with placebo).

RELATED: Managing PD-1 Inhibitor-induced Pneumonitis

Toxicities were higher in the vandetanib group than for those receiving placebo.

The authors concluded that adding vandetanib to platinum therapy and etoposide does not benefit patients with SCLC. Vascular endothelial growth factor status did not affect treatment outcomes.

Reference

  1. Sanborn RE, Patel JD, Masters GA, et al. A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113. Cancer. 2016 Sep 1. doi: 10.1002/cncr.30287 [Epub ahead of print]